Cover Image
市場調查報告書

美國皮膚癌治療藥的開發平台分析

US Skin Cancer Drug Pipeline Analysis

出版商 PNS Pharma 商品編碼 302555
出版日期 內容資訊 英文 310 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
美國皮膚癌治療藥的開發平台分析 US Skin Cancer Drug Pipeline Analysis
出版日期: 2014年01月14日 內容資訊: 英文 310 Pages
簡介

美國皮膚癌治療藥由於患者數的增加及開發階段的新治療藥的出現等影響,預測將有莫大的成長。再加上主要已上市醫藥品的有機成長,是其他主要的成長要因。美國的皮膚癌市場屬黑色素瘤(Melanoma)最為常見。黑色素瘤的比例僅佔皮膚癌整體的5%,但卻是75%的致死原因。此外,美國市場以補助(佐劑)療法來治療早期黑色素瘤比起其他國家都要繁盛。

本報告詳細調查在美國正在開發的各種皮膚癌治療藥,為您概述為以下內容。

第1章 美國的皮膚癌市場概要

第2章 皮膚癌治療藥臨床階段:不明

  • 概要
  • 皮膚癌治療藥臨床階段的簡介

第3章 皮膚癌治療藥臨床階段:研究

  • 概要
  • 皮膚癌治療藥臨床階段的簡介

第4章 皮膚癌治療藥臨床階段:臨床試驗前

  • 概要
  • 皮膚癌治療藥臨床階段的簡介

第5章 皮膚癌治療藥臨床階段:臨床試驗

  • 概要
  • 皮膚癌治療藥臨床階段的簡介

第6章 皮膚癌治療藥臨床階段:階段0

  • 概要
  • 皮膚癌治療藥臨床階段的簡介

第7章 皮膚癌治療藥臨床階段:階段I

  • 概要
  • 皮膚癌治療藥臨床階段的簡介

第8章 皮膚癌治療藥臨床階段:階段I/II

  • 概要
  • 皮膚癌治療藥臨床階段的簡介

第9章 皮膚癌治療藥臨床階段:階段II

  • 概要
  • 皮膚癌治療藥臨床階段的簡介

第10章 皮膚癌治療藥臨床階段:階段III

  • 概要
  • 皮膚癌治療藥臨床階段的簡介

第11章 皮膚癌治療藥臨床階段:登記完畢

  • 概要
  • 皮膚癌治療藥臨床階段的簡介

第12章 上市

  • 概要
  • 已上市皮膚癌治療藥簡介
目錄

The market for skin cancer in the US is expected to grow significantly owing to reasons like increasing number of patients and entry of new therapies which are in the pipeline. Additionally, the organic growth of key marketed drugs is also another major factor driving the growth in the US market. Of the different types of skin cancers in the US, Melanoma is the most common. Though this segment accounts for just 5% of the overall US skin cancer market, it is a major factor causing 75% deaths in the region. Also, the US market witnesses a greater use of adjuvant therapy to treat early stage melanoma, as compared to the other regions.

With surgery being along with early detection is by far the most successful method of treating skin cancer in the US, the risk of recurrence in the patients is high. Additionally, the survival rates for the patients with advanced stages of the disease are very low. This has been a major challenge in the US market and companies investing in this space have been continuously researching on various options to improve the survival rates.

"US Skin Cancer Drug Pipeline Analysis" by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of skin cancer in US. Research report covers all drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the US skin cancer drug market based upon development process.

Following parameters for each drug profile in development phase are covered in "US Skin Cancer Drug Pipeline Analysis" research report:

  • Drug Profile Overview
  • Alternate Names for Drug
  • Active Indication
  • Phase of Development
  • Mechanism of Action
  • Brand Name
  • Patent Information
  • Orphan Designation by Indication, Country & Organisation
  • Country for Clinical Trial
  • Owner / Originator/ Licensee/Collaborator
  • Administrative Route
  • Drug Class
  • ATC Codes

Number of Skin Cancer Drug in Pipeline by Clinical Phase:

  • Research: 3
  • Preclinical: 29
  • Clinical: 5
  • Phase 0: 1
  • Phase-I: 29
  • Phase-I/II: 18
  • Phase-II: 41
  • Phase-III: 13
  • Registered: 4
  • Marketed: 18
  • Unknown: 1

Table of Contents

1. US Skin Cancer Drug Market Overview

2. Skin Cancer Drug Clinincal Phase: Unknown

  • 2.1. Overview
  • 2.2. Skin Cancer Drug Profile in Clinical Phase

3. Skin Cancer Drug Clinincal Phase: Research

  • 3.1. Overview
  • 3.2. Skin Cancer Drug Profile in Clinical Phase

4. Skin Cancer Drug Clinincal Phase: Preclinical

  • 4.1. Overview
  • 4.2. Skin Cancer Drug Profile in Clinical Phase

5. Skin Cancer Drug Clinincal Phase: Clinical

  • 5.1. Overview
  • 5.2. Skin Cancer Drug Profile in Clinical Phase

6. Skin Cancer Drug Clinincal Phase: Phase-0

  • 6.1. Overview
  • 6.2. Skin Cancer Drug Profile in Clinical Phase

7. Skin Cancer Drug Clinincal Phase: Phase-I

  • 7.1. Overview
  • 7.2. Skin Cancer Drug Profile in Clinical Phase

8. Skin Cancer Drug Clinincal Phase: Phase-I/II

  • 8.1. Overview
  • 8.2. Skin Cancer Drug Profile in Clinical Phase

9. Skin Cancer Drug Clinincal Phase: Phase-II

  • 9.1. Overview
  • 9.2. Skin Cancer Drug Profile in Clinical Phase

10. Skin Cancer Drug Clinincal Phase: Phase-III

  • 10.1. Overview
  • 10.2. Skin Cancer Drug Profile in Clinical Phase

11. Skin Cancer Drug Clinincal Phase: Registered

  • 11.1. Overview
  • 11.2. Skin Cancer Drug Profile in Clinical Phase

12. Marketed

  • 12.1. Overview
  • 12.2. Marketed Skin Cancer Drug Profile

List of Table

Each Drug Profile has Tables Representing Following Information:

  • Alternate Names
  • Originator & Owner
  • Collaborator
  • Technology Provider
  • Licensee
  • Highest Development Phase
  • Indications
  • Class
  • Mechanism of Action
  • ATC Code
  • Designated Brand Name
Back to Top